Navigation Links
Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin
Date:11/1/2009

Alternative Medicine is Currently Offering a Blueberry Extract with a compound that fights chronic liver disease Infections caused by Hepatitis C. Lloyd Wright survived Hepatitis and has in fact been deemed free from a malady that doctors claim is incurable. The Blueberry Extract has a compound derived from blueberry leaves and is very powerful, Lloyd's extract is the only one on the market with 45% Proanthocyanidin

Los Angeles (PRWEB) November 1, 2009 -- Lloyd Wright, author of Triumph Over Hepatitis C and President of Alternative Medicine, Inc., is currently marketing the only Blueberry Extract which contains 45% Proanthocyanidin, a powerful compound derived from blueberry leaves which has proved a potent inhibitor of Hepatitis C virus (HCV) infections. Wright, whose company offers a wide of variety of natural products to combat Hepatitis C, has a simple message for anyone taking other blueberry extracts: "If the blueberry extract you are taking does not say PROANTHOCYANIDIN on the label, it is not helping stop Hepatitis C. Our Blueberry extract is the only one the market today which contains 45% Proanthocyanidin."

The story of Lloyd Wright's Blueberry Extract is an interesting one. First, Hepatitis C virus (HCV) infection is a major cause of chronic liver disease such as chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Then, while searching for new natural anti-HCV agents in agricultural products, we found a potent inhibitor of HCV RNA expression in extracts of blueberry leaves when examined in an HCV subgenomic replicon cell culture system.

This activity was observed in a methanol extract fraction of blueberry leaves and was purified by repeated fractionations in reversed-phase high-performance liquid chromatography. The final purified fraction showed a 63-fold increase in specific activity compared with the initial methanol extracts and was composed
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Lloydspharmacy Reveals Hayfever Misery to Hit One in Two People by 2060
2. Darwins Kim Lloyd to Speak on Panel at American Hospital Association Solutions Roundtable, June 3, 2009
3. Lloyd I. Miller III Announces Voting Intentions for United American Healthcares Annual Meeting
4. Ricky Tomlinson Joins Lloydspharmacy Against Coronary Heart Disease
5. InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group
6. Delaware Hospice Honors President and CEO Susan D. Lloyd, MSN, RN
7. An Alternative To Adderall?
8. Survey Reveals Parents Are Eager to Learn about Alternative Medicine Options but Information is Lacking
9. The Obamacare Alternative: 33 State Think Tanks Announce Patient-Centered Health Care Reforms
10. California Surgeon (laserbacksurgery.com) Pioneers Exciting Alternative to Traditional Spinal Stenosis Treatment
11. SinusWars LLC Launches a Successful and All Natural Alternative to Antibiotics in the Fight to Treat Chronic Sinusitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... London, UK (PRWEB) August 22, 2014 ... more magnetic for some clinical applications due to ... of the emerging innovations in ultrasound, such as ... imaging, are expected to keep the market moving ... as increasing mobility can enhance not only the ...
(Date:8/22/2014)... 2014 Testosterone treatment lawsuits ( ... courts on behalf of men who allegedly suffered ... prescription low testosterone therapies, Bernstein Liebhard LLP reports. ... filed against Pfizer Inc. on July 31st by ... issues due to his use of Depo-Testosterone. (Case ...
(Date:8/22/2014)... Eagerly embracing intended parents around the globe, ... offers the top male infertility programs — run by ... network of IVFinMexico.com continues to shape modern ... female and male infertility, advanced research and education. , ... eminently set by company CEO and Founder Tolga Umar ...
(Date:8/22/2014)... 2014 Mueller Sports Medicine is excited ... exciting new product that provides non-drug instant relief for ... while you heal. The package includes 7 days of ... technology – it is not kinesiology tape. It’s made ... System for Plantar Fasciitis is a breakthrough in ...
(Date:8/22/2014)... CarePoint Health is proud to ... Geriatrics, Hospice and Palliative Care, Dr. Michelle Reisner, ... Their system welcomes Dr. Reisner to the community. ... CarePoint Health Medical Group, a comprehensive network of ... a wide range of specialties. This latest acquisition ...
Breaking Medicine News(10 mins):Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 2Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 3Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 4Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Dr. Reisner Joins CarePoint Health Medical Group 2
... birth but develop accelerated head growth between six and ... onset of many behaviors that enable physicians to diagnose ... University of Washingtons Autism Center., The study also indicates ... have the early onset form of autism as well ...
... Store,s Gift of Mobility Fulfills Dreams of Terminally Ill,Stage Performer, ... his life in the public eye - whether he was ... or appearing in,television commercials. But two years ago, cancer robbed ... past year. To fulfill his,dream to get outside again, The ...
... BOCA RATON, Fla., Jan. 30 Spirit of ... bidding for the Spirit of Women,Celebrity Red Shoe ... will benefit several health,organizations, including the National Stroke ... for auction February 5,through February 14 were autographed ...
... Web address on all TV ads to report adverse,reactions, ... ads that sell the "good news" about prescription drugs,but ... on a petition to the FDA demanding the agency ... medications., The citizens, petition requests the Food and ...
... LANSING, Jan. 30 A report issued today ... policy consultancy,based in Washington, D.C., confirms that Blue ... million to the people of Michigan in 2007 ... to improve access to,health coverage at affordable prices. ...
... known to doctors as a hormone that boosts red-blood-cell production. ... PhD, an ophthalmologist at Children,s Hospital Boston, shows it also ... The findings not only add a new function to the ... prescribing it to patients with diseases affected by abnormal blood-vessel ...
Cached Medicine News:Health News:Accelerated head growth can predict autism before behavioral symptoms start 2Health News:Former Actor has Mobility Restored With Power Wheelchair Gift From The Scooter Store 2Health News:Celebrities Encourage Women to Take Steps for Heart Health Through Online Red Shoe Charity Auction 2Health News:Petition Asks FDA to Make it Easier for Patients to Report Side Effects from Prescription Drugs 2Health News:Examination by National Expert Shows Blue Cross Blue Shield of Michigan's Social Mission Contributions Totaled at Least $391 Million in 2007 2Health News:Examination by National Expert Shows Blue Cross Blue Shield of Michigan's Social Mission Contributions Totaled at Least $391 Million in 2007 3Health News:Anemia treatment may be a double-edged sword 2Health News:Anemia treatment may be a double-edged sword 3
(Date:8/22/2014)... -- Research and Markets  has announced the addition ... & Technologies" report to their offering. ... or you wish to expand your product line, you,ll ... The authors know you want to make effective product ... generate improved revenues and take market share from your ...
(Date:8/22/2014)... , Aug. 22, 2014  Dr. Mark Rasak ... the Diamond Lifetime Achievement Award in the field of ... of Cardiovascular Clinical Associates. Dr. Rasak has ... all major aspects of the business; overseeing the daily ... primary coronary intervention. In addition, he is an honored ...
(Date:8/22/2014)... Ohio , Aug. 22, 2014 MC Medical, ... Inc. (MID), a Columbus, OH medical ... distribute the FloShield laparoscopic and robotic visualization system in ... be approved for sale in Japan ... a long-time experience and an extensive product portfolio in endoscopic ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2
... of trial triggers $10 million milestone payment to PharmassetPRINCETON, ... VRUS ) and Roche (Roche SWX: RO, ROG; Pink ... been dosed in a Phase IIb study of R7128, ... the treatment of chronic hepatitis C (HCV). The trial ...
... to Initiate in 2010 for BlinatumomabNEW YORK, April 24 ... biopharmaceutical company developing novel, proprietary antibodies for the treatment ... R&D Day for investors and financial analysts at The ... highlighted significant areas of development across Micromet,s BiTE antibody ...
Cached Medicine Technology:Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 2Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 4